Treatment with a selective inhibitor of PI3Kβ, a PI3K isoform that can activate AKT activity in cancer cells but is dispensable for T-cell receptor activation and signaling, improved the efficacy of both anti-PD1 and anti-CTLA4 in a model of PTEN-depleted melanoma cells [93]. This evidence concerns the gene AKT1 and cancer.